A practical reference on albumin binding: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-05-25 and is reviewed periodically as new material appears.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | 39-residue synthetic peptide |
| Average molecular mass | About 4813.5 Da | Free base form |
| Appearance | White to off-white powder | Solid after lyophilization |
| Solubility class | Freely soluble in water | Also soluble in neutral aqueous buffers |
| Typical storage | At or below -20 °C, desiccated | Protect from light and moisture |
纯度评估通常综合反相色谱、体积排阻色谱与质谱三方面信息：前者反映疏水性杂质，后者反映聚集体，质谱则确认分子量与主要降解产物。有关降解途径的完整图谱——例如脱酰胺、氧化与水解各占多大比例——在不同储存条件下仍有差异，属于需要逐案验证的问题。
质量控制环节关注外观、含量、纯度、有关物质、水分与微生物限度等项目。检测结果需要有对照品和系统适用性数据支持，单次测定不足以判定批次的稳定性。实验室之间方法转移时，色谱柱品牌与梯度差异常导致保留时间漂移，因此方法验证十分必要。
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Tumor biopsy samples used for diagnostics always contain as little as 5% of the target variant as compared to wildtype sequence. Also, for noninvasive applications from peripheral blood or urine, the DNA test must be specific enough to detect mutations at variant allele frequencies of less than 0.1%. Currently, by optimizing the traditional PCR, there's a new invention, amplification-refractory mutation system (ARMS) is a method for detecting DNA sequence variants in cancer. The principle behind ARMS is that the enzymatic extension activity of DNA polymerases is highly sensitive to mismatches near the 3' end of primer. Many different companies have developed diagnostics tests based on ARMS PCR primers. For instance, Qiagen therascreen, Roche cobas and Biomerieux THxID have developed FDA approved PCR tests for detecting lung, colon cancer and metastatic melanoma mutations in the KRAS, EGFR and BRAF genes. Their IVD kits were basically validated on genomic DNA extracted from FFPE tissue. There are also microarrays that utilize hybridization mechanism to diagnose cancer. More than a million of different probes can be synthesized on an array with Affymetrix's Genechip technology with a detection limit of one to ten copies of mRNA per well. Optimized microarrays are typically considered to produce repeatable relative quantitation of different targets.
Sulfurous acid, which is unstable, forms stable dimethyl sulfite ((CH3−O−)2S=O) Dicarbonic acid, which is unstable, forms stable dimethyl dicarbonate (CH3−O−C(=O)−O−C(=O)−O−CH3) In principle, a part of metal and metalloid alkoxides, of which many hundreds are known, could be classified as esters of the corresponding acids (e.g., aluminium triethoxide (Al(OCH2CH3)3) could be classified as an ester of aluminic acid which is aluminium hydroxide, tetraethyl orthosilicate (Si(OCH2CH3)4) could be classified as an ester of orthosilicic acid, and titanium ethoxide (Ti(OCH2CH3)4) could be classified as an ester of orthotitanic acid).
Symptoms of intoxication from overdose include drowsiness, insomnia, stupor, agitation, coma, transient confusion, increased anxiety, ataxia, convulsions, oliguria, anuria, tachycardia or bradycardia, arrhythmia, AV block, hypotension, shock, respiratory depression, and, rarely, cardiac arrest.
BCG vaccine should be given intradermally. If given subcutaneously, it may induce local infection and spread to the regional lymph nodes, causing either suppurative (production of pus) or nonsuppurative lymphadenitis. Conservative management is usually adequate for nonsuppurative lymphadenitis. If suppuration occurs, it may need needle aspiration. For unresolved suppuration, surgical excision may be required. Evidence for the treatment of these complications is scarce. Uncommonly, breast and gluteal abscesses can occur due to haematogenous (carried by the blood) and lymphangiomatous spread. Regional bone infection (BCG osteomyelitis or osteitis) and disseminated BCG infection are rare complications of BCG vaccination, but potentially life-threatening. Systemic antituberculous therapy may be helpful in severe complications. When BCG is used for bladder cancer, around 2.9% of treated patients discontinue immunotherapy due to a genitourinary or systemic BCG-related infection, however while symptomatic bladder BCG infection is frequent, the involvement of other organs is very uncommon. When systemic involvement occurs, liver and lungs are the first organs to be affected (1 week [median] after the last BCG instillation). If BCG is accidentally given to an immunocompromised patient (e.g., an infant with severe combined immune deficiency), it can cause disseminated or life-threatening infection. The documented incidence of this happening is less than one per million immunizations given.
Sources: en.wikipedia.org
=== Medications === Pentoxifylline is a useful add-on treatment to compression stockings and may also help by itself. It works by reducing platelet aggregation and thrombus formation. Gastrointestinal disturbances were reported as a potential adverse effect. Sulodexide, which reduces the formation of blood clots and reduces inflammation, may improve the healing of venous ulcers when taken in conjunction with proper local wound care. Further research is necessary to determine potential adverse effects, the effectiveness, and the dosing protocol for sulodexide treatment. An oral dose of aspirin is being investigated as a potential treatment option for people with venous ulcers. A 2016 Cochrane systematic review concluded that further research is necessary before this treatment option can be confirmed to be safe and effective. Oral zinc supplements have not been proven to be effective in aiding the healing of venous ulcers; however, more research is necessary to confirm these results. Treatments aimed at decreasing protease activity to promote healing in chronic wounds have been suggested; however, the benefit remains uncertain. There is also a lack of evidence on the effectiveness of testing for elevated proteases in venous ulcers and treating them with protease-modulating treatment. There is low certainty evidence that protease modulating matrix treatment is helpful in the healing of venous ulcers. Flavonoids may be useful for treating venous ulcers, but the evidence must be interpreted cautiously.
Pressed and dried: Vascular plant (flowering plants, conifers, ferns) specimens are pressed and dried plants that are mounted on herbarium sheets. Various techniques are used to attach the plants with the most common method of using archival adhesive with heavier portions of the plant supported additionally by linen thread or narrow strips of gum-backed linen tape or polyester film. Specimens are best pressed with moderate pressure, permitting as much air circulation as possible. This is commonly achieved by strapping sheets in a press made of heavy cardboard or plywood. If there are loose seeds or fruits, these are placed in a small fragment packet, which also is glued to the sheet. A label with collection information is glued on the bottom right corner. Dried: Small bryophytes (mosses, hepatics or liverworts, and hornworts) are dried and placed loosely in folded packets. The label is glued on the front of the packet and the packets are filed loosely in boxes, glued to sheets of mounting paper, or placed loosely in folders. Stored in fluid: Preserved material can be kept in a glass jar filled with preservative fluid. By storing this way, the botanical specimens are maintained in a usable condition by inhibiting enzymatic and microbial attack. This method can be used where drying, pressing and mounting on a herbarium sheet is unsuitable. This method allows for a better three-dimensional arrangement of flower parts or fruits for storage.
Today the Catholic devotions to the Holy Face of Jesus are usually associated with the negative image of the Shroud of Turin, as first captured in Secondo Pia's 1898 photograph. However, these devotions predate Pia's image, having been established in 1844 by the Carmelite nun Marie of St Peter, based on depictions of Jesus before his crucifixion and associated with the tradition of the Veil of Veronica. This devotion was then promoted by a French Catholic layman, Leo Dupont, who became known as the "Apostle of the Holy Face". In 1851 Dupont formed the "Archconfraternity of the Holy Face" in the city of Tours. Pope Leo XIII approved the devotion to the Holy Face in 1885. The popular French Saint Thérèse of Lisieux took the name "Thérèse of the Child Jesus and the Holy Face" when she became a Discalced Carmelite in 1889. Saint Thérèse, who died in 1897, also helped to spread the devotion to the Holy Face before it became associated with Pia's photographic image of the Shroud of Turin. The modern devotion to the Holy Face centered on the negative photographic image from the Shroud of Turin derives principally from an Italian nun born in Milan, Maria Pierina De Micheli, who reported having visions of Jesus starting in 1936. Sister Maria Pierina designed a "Holy Face Medal", based on Secondo Pia's photographs. This medal was eventually approved for private devotion by Pope Pius XII.
Hemoglobin H disease, also called α-thalassemia intermedia, is a disease affecting hemoglobin, the oxygen carrying molecule within red blood cells. It is a form of α-thalassemia which most commonly occurs due to deletion of 3 out of 4 of the α-globin genes.
==== Multiple sclerosis-related fatigue ==== Fatigue is a common and often debilitating symptom experienced by people with multiple sclerosis. Reviews and meta-analyses of controlled trials have found that modafinil has modest effectiveness in managing MS-related fatigue, though improvements in fatigue severity scores have not consistently reached statistical significance. Optimal dosing and treatment schedules are not well established. Clinical assessments have found that adverse events were common. Most MS organizations are neutral on the off-label use of modafinil to alleviate fatigue associated with MS.
Sources: en.wikipedia.org
=== 3 February === Abdallah Hussein, a senior RSF commander was killed by an SAF airstrike in al-Kamelin in Gezira State. The SAF claimed to have broke the siege of its Corps of Engineers garrison in the Al 'Aylafun area, and retook the al-Asaylat, Um Daw Ban, and Al 'Aylafun areas of the East Nile locality. The SAF said it plans to continue advances to recapture the Soba Bridge. According to the state health minister of South Kordofan, the SPLM-N (al-Hilu) killed 44 people after shelling the main market, residential neighborhoods, and temporary shelters in schools in Kadugli. Twenty-five people were killed in an SAF airstrike in Nyala.
=== Inflammation === In inflammatory conditions, fibrinogen, other clotting proteins, and alpha globulin are positively charged, thus increasing the ESR. ESR begins to rise at 24 to 48 hours after the onset of acute self-limited inflammation, decreases slowly as inflammation resolves, and can take weeks to months to return to normal levels. For ESR values more than 100 mm/hour, there is a 90% probability that an underlying cause would be found upon investigation.
5-HT3 antagonists (e.g. ondansetron) Dopamine antagonists (e.g. domperidone) Anti-cholinergic antihistamines (e.g. diphenhydramine) Δ9-tetrahydrocannabinol (e.g. dronabinol) Vomiting is due to gastric stasis (large volume vomiting, brief nausea relieved by vomiting, oesophageal reflux, epigastric fullness, early satiation), besides direct action on the chemoreceptor trigger zone of the area postrema, the vomiting centre of the brain. Vomiting can thus be prevented by prokinetic agents (e.g. domperidone or metoclopramide). If vomiting has already started, these drugs need to be administered by a non-oral route (e.g. subcutaneous for metoclopramide, rectally for domperidone).
=== Motivational disorders === Selegiline has been found to produce pro-motivational effects and to reverse motivational deficits in rodents. In case reports and small clinical studies, selegiline has been reported to improve disorders of diminished motivation like apathy and abulia due to conditions such as traumatic brain injury. In accordance with the preceding findings, selegiline, along with other dopaminergic and activating agents, may be useful in the treatment of disorders of diminished motivation, including apathy, abulia, and akinetic mutism.
Sources: en.wikipedia.org
It is a synthetic peptide and a dual agonist of two incretin receptors. It is not a small molecule, and it is not structurally related to the older single-receptor peptide agonists.
The C20 fatty diacid promotes tight binding to serum albumin. That binding reduces renal clearance and extends circulation time compared with an unmodified peptide of similar length.
It is not fully established. Studies indicate that both receptors contribute to the observed effects, but the exact split between the two signaling pathways in humans remains an open question.
It is normally kept frozen, desiccated, and away from light, with brief warming to room temperature before opening to limit condensation. Repeated freeze-thaw cycles are avoided because they stress the peptide. Once in solution, the material is held cold and used promptly.